Attendance at the live virtual session is required to earn CME credit. Credit is issued only to participants who attend the full program and complete the required post-activity evaluation.
Chronic inflammatory skin diseases like psoriasis, hidradenitis suppurativa, atopic dermatitis, and alopecia areata are now recognized as significant risk factors for cardiovascular disease. Meanwhile, cardiovascular conditions—like infective endocarditis, heart failure, and thromboembolism—can present with key skin findings that aid in diagnosis. This session explores the bidirectional relationship between skin and heart health, highlighting how therapies in one domain can impact the other, and emphasizes the need for interdisciplinary awareness. Despite growing evidence, clear screening guidelines for cardiovascular risk in dermatologic patients remain limited, making education and early recognition essential for improving outcomes.
Sponsored by Arcutis Biotherapeutics, Inc.
Psoriasis is a chronic autoimmune disease that affects approximately 8 million people in the US and places a substantial physical, psychological, and social burden on patients. [i]Despite therapeutic advances, management remains difficult due to poor adherence and patient dissatisfaction with current options. Injectable biologics offer durable control but are often limited by barriers such as injection fatigue, needle aversion, and costs. Oral therapies provide a convenient alternative by targeting systemic inflammation without injections. This session will appropriately position these therapies by comparing efficacy and safety across oral and injectable agents, and outline strategies for determining which patients are most likely to benefit from oral versus injectable approaches.
After participating in this educational initiative, learners should be able to:
• Examine limitations of injectable biologics in psoriasis, including barriers to adherence and patient preference for non-injectable options
• Assess the safety/efficacy data and mechanisms of action of current and emerging oral therapies for moderate-to-severe PsO, including head-to-head comparisons and long-term data
• Identify strategies to determine when patients may benefit from oral versus injectable treatment approaches
Supported by an educational grant from Johnson & Johnson.
Sponsored by Sun Pharma.
The evolving concept of remission in dermatology is reshaping clinical expectations and research strategies. Recently, the National Psoriasis Foundation introduced a distinction between on-drug remission and off-drug remission. The International Eczema Council is working on similar distinctions. Faculty will discuss these new concepts that continue to gain traction as standards in research and practice.
Sponsored by Regeneron Pharmaceuticals, Inc.
Despite advances in Th2- and JAK/STAT-targeted therapies, many patients with atopic dermatitis (AD) continue to experience residual symptoms, especially pruritus. New approaches are exploring IL-31 inhibition and refined JAK-STAT modulation to address persistent itch, particularly in “clear-skin, persistent-itch” phenotypes. Additional targets include TSLP, IL-1 family cytokines, OX40/OX40L, and Th17/Th22 pathways. Adjunctive device-based modalities—such as phototherapy, transcutaneous electrical nerve stimulation, and cold plasma therapy—are also under investigation. This session will provide an overview of these next-generation therapies.
Sponsored by SUN Pharmaceutical Industries, Inc.
Cutaneous lupus erythematosus (CLE) is an interferon-driven autoimmune skin disease with three main subtypes—acute (ACLE), subacute (SCLE), and chronic (CCLE), including discoid lupus erythematosus and related variants. Overlap with systemic lupus erythematosus (SLE) and other dermatologic conditions complicates diagnosis and management, underscoring the importance of early recognition to prevent irreversible damage. Conventional treatments are often nonspecific, slow to act, and limited by tolerability and monitoring concerns, whereas emerging targeted therapies show promise. Given its chronic, relapsing course, optimized outcomes require multidisciplinary care and continued clinician education to improve diagnosis, treatment, and patient quality of life.
After participating in this educational initiative, learners should be able to: • Describe the pathogenesis, clinical variations, and diagnosis of acute, subacute, and chronic CLE to support comprehensive assessment and timely treatment • Evaluate current clinical data associated with available and emerging treatment options for CLE • Implement evidence-based and individualized CLE care that incorporates an interdisciplinary approach to management
Supported by an educational grant from Biogen.
Join a panel of leading dermatology experts for a dynamic, interactive Q&A session addressing the most pressing questions facing today’s dermatology practices. This session will focus on real-world clinical challenges, emerging trends, and practical strategies to optimize patient care, practice efficiency, and clinical decision-making. Attendees will have the opportunity to engage directly with faculty, gain expert insights on controversial and evolving topics, and leave with actionable takeaways they can immediately apply in practice on Monday.
Be prepared for anything after this session, which will discuss recent advances in hidradenitis suppurativa treatments. Biologic therapies and small-molecule drugs have expanded treatment options by targeting key components of the disease's immunopathogenesis. Biologics, including TNF-α inhibitors and interleukin-targeting agents, have demonstrated efficacy in reducing inflammation, abscess formation, and disease progression, while improving quality of life. Meanwhile, small-molecule therapies offer advantages such as oral delivery, novel intracellular targets, and immune modulation. Ongoing research is optimizing the use of these agents, exploring their long-term outcomes, and investigating combination approaches.
Join an open, podcast-style conversation with leading dermatology faculty as they discuss the latest research shaping the field and spotlight high-interest, underserved areas of clinical practice. In this informal, engaging format, faculty will share expert perspectives, real-world experiences, and honest insights into emerging data, controversies, and gaps in care. Designed to spark thoughtful dialogue, this session offers attendees a fresh, accessible look at cutting-edge science and underrepresented topics, with practical takeaways to inform patient care and future research.
